Thromboprophylaxis and anticoagulation for inpatients with COVID-19 in 2022 and beyond

Abstract

In spring 2020, small observational studies suggested that COVID-19 was associated with a high risk for thromboembolic events, mainly within the venous compartment (VTE) as pulmonary embolism (PE) and deep venous thrombosis in patients managed in intensive care units (ICU). Despite lack of data from randomized clinical trials, guidelines on thromboprophylaxis and anticoagulation (AC) rapidly emerged with recommendations on thromboprophylaxis for most patients hospitalized with COVID-19 and intermediate or therapeutic dose AC for ICU patients, endorsed by international societies.